Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.

Seiden MV, Neubauer M, Verrilli D.

Am J Manag Care. 2017 Feb;23(2 Spec No.):SP69-SP77. No abstract available.

2.
3.

The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites.

Cella D, Neubauer N, Thomas J, Kutner J, Seiden MV.

Gynecol Oncol. 2013 Feb;128(2):187-90. doi: 10.1016/j.ygyno.2012.11.013. Epub 2012 Nov 15.

PMID:
23159815
4.
5.

Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.

Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM.

Clin Cancer Res. 2012 Jun 1;18(11):3197-206. doi: 10.1158/1078-0432.CCR-12-0056. Epub 2012 Apr 5.

6.

Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems.

van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM.

AAPS J. 2010 Jun;12(2):171-80. doi: 10.1208/s12248-010-9174-4. Epub 2010 Feb 9.

7.

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.

Sarosy GA, Hussain MM, Seiden MV, Fuller AF, Nikrui N, Goodman A, Minasian L, Reed E, Steinberg SM, Kohn EC.

Cancer. 2010 Mar 15;116(6):1476-84. doi: 10.1002/cncr.24861.

8.

Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.

Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT.

Gynecol Oncol. 2010 Feb;116(2):168-72. doi: 10.1016/j.ygyno.2009.10.075. Epub 2009 Nov 18.

PMID:
19922985
9.

CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.

Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R.

Stem Cells. 2009 Dec;27(12):2875-83. doi: 10.1002/stem.236.

10.

Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.

Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT.

J Allergy Clin Immunol. 2009 Jun;123(6):1262-7.e1. doi: 10.1016/j.jaci.2009.02.042.

PMID:
19501233
11.

Progress in gynecologic cancer.

Seiden MV.

Semin Oncol. 2009 Apr;36(2):90. doi: 10.1053/j.seminoncol.2008.12.010. No abstract available.

PMID:
19332243
12.

Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.

van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM.

Mol Pharm. 2008 Jul-Aug;5(4):516-26. doi: 10.1021/mp800030k. Epub 2008 Jul 11.

13.

CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.

Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H, Seiden MV.

Cancer Chemother Pharmacol. 2009 Mar;63(4):681-9. doi: 10.1007/s00280-008-0785-8. Epub 2008 Jun 28.

14.

Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.

Devalapally H, Duan Z, Seiden MV, Amiji MM.

Clin Cancer Res. 2008 May 15;14(10):3193-203. doi: 10.1158/1078-0432.CCR-07-4973.

15.

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10. doi: 10.1073/pnas.0712237105. Epub 2008 Feb 19.

16.

Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells.

Friel AM, Sergent PA, Patnaude C, Szotek PP, Oliva E, Scadden DT, Seiden MV, Foster R, Rueda BR.

Cell Cycle. 2008 Jan 15;7(2):242-9. Epub 2007 Oct 24.

PMID:
18256549
18.

Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.

Sakamoto H, Friel AM, Wood AW, Guo L, Ilic A, Seiden MV, Chung DC, Lynch MP, Serikawa T, Munro E, Oliva E, Orsulic S, Kirley SD, Foster R, Zukerberg LR, Rueda BR.

Cancer Biol Ther. 2008 Feb;7(2):180-88. Epub 2007 Nov 15.

PMID:
18059193
19.

8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.

Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV.

Mol Pharmacol. 2007 Nov;72(5):1137-45. Epub 2007 Aug 3.

PMID:
17675586
20.
21.

Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.

van Vlerken LE, Duan Z, Seiden MV, Amiji MM.

Cancer Res. 2007 May 15;67(10):4843-50.

22.

Case records of the Massachusetts General Hospital. Case 13-2007. A 46-year-old woman with gynecologic and intestinal cancers.

Seiden MV, Patel D, O'Neill MJ, Oliva E.

N Engl J Med. 2007 Apr 26;356(17):1760-9. No abstract available.

PMID:
17460231
23.
24.

Pooling of case specimens to create standard serum sets for screening cancer biomarkers.

Skates SJ, Horick NK, Moy JM, Minihan AM, Seiden MV, Marks JR, Sluss P, Cramer DW.

Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41.

25.

Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.

Berkenblit A, Eder JP Jr, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):584-90.

26.

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.

Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F.

Gynecol Oncol. 2007 Mar;104(3):727-31. Epub 2006 Nov 28.

PMID:
17126894
27.

SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.

Duan Z, Bradner JE, Greenberg E, Levine R, Foster R, Mahoney J, Seiden MV.

Clin Cancer Res. 2006 Nov 15;12(22):6844-52.

28.

Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31. Epub 2006 Nov 6.

29.

Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.

Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV.

Clin Cancer Res. 2006 Sep 1;12(17):5055-63.

30.

Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy.

del Carmen MG, Findley M, Muzikansky A, Roche M, Verrill CL, Horowitz N, Seiden MV.

Gynecol Oncol. 2007 Jan;104(1):70-6. Epub 2006 Sep 1.

PMID:
16949138
31.

Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.

Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV; Dana-Farber/Partners CancerCare and Harvard Vanguard Medical Associates.

Gynecol Oncol. 2006 Nov;103(2):575-80. Epub 2006 Jun 23.

PMID:
16806439
32.

Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma.

Littell RD, Hallonquist H, Matulonis U, Seiden MV, Berkowitz RS, Duska LR.

Gynecol Oncol. 2006 Nov;103(2):570-4. Epub 2006 Jun 12.

PMID:
16769104
33.

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.

Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD.

Mol Cancer Ther. 2006 Apr;5(4):952-61.

34.

Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.

Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A; Gynecologic Cancer Program of Dana Farber-Harvard Cancer Center.

Gynecol Oncol. 2006 Oct;103(1):160-4. Epub 2006 Mar 29.

PMID:
16566993
35.

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.

Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, Falke T, Lambert J, Seiden MV.

J Clin Oncol. 2006 Feb 1;24(4):571-8.

PMID:
16446329
36.

Reclassification of a tubal leiomyosarcoma as an eGIST by molecular evaluation of c-KIT.

Foster R, Solano S, Mahoney J, Fuller A, Oliva E, Seiden MV.

Gynecol Oncol. 2006 May;101(2):363-6. Epub 2006 Jan 24.

PMID:
16439005
37.

Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.

Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.

J Pain Symptom Manage. 2005 Dec;30(6):563-9.

PMID:
16376743
38.

A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.

Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF Jr, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA; Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare.

Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1035-41.

39.

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP 3rd.

Gynecol Oncol. 2006 Apr;101(1):55-61. Epub 2005 Nov 2.

PMID:
16260029
40.

Topotecan: weighing in when there are many options.

Penson RT, Seiden MV.

Oncologist. 2005 Oct;10(9):698-700.

41.

Laughter: the best medicine?

Penson RT, Partridge RA, Rudd P, Seiden MV, Nelson JE, Chabner BA, Lynch TJ Jr.

Oncologist. 2005 Sep;10(8):651-60. Review.

42.

Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.

Klein A, He X, Roche M, Mallett A, Duska L, Supko JG, Seiden MV.

Gynecol Oncol. 2006 Jan;100(1):205-9. Epub 2005 Sep 19.

PMID:
16171852
43.

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.

Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H.

J Clin Oncol. 2005 Aug 20;23(24):5597-604.

PMID:
16110019
44.

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD.

J Clin Oncol. 2005 Aug 20;23(24):5484-92.

PMID:
16110008
45.

GBP1 overexpression is associated with a paclitaxel resistance phenotype.

Duan Z, Foster R, Brakora KA, Yusuf RZ, Seiden MV.

Cancer Chemother Pharmacol. 2006 Jan;57(1):25-33. Epub 2005 Nov 5.

PMID:
16028104
46.

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.

Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP.

Br J Cancer. 2005 Jul 11;93(1):54-9.

47.

Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.

Bendell JC, Eder JP, Clark JW, Fidias P, Lynch TJ, Seiden MV, Ryan DP.

Cancer. 2005 May 1;103(9):1925-31.

48.

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.

Vaidya AP, Parnes AD, Seiden MV.

Curr Treat Options Oncol. 2005 Mar;6(2):103-14. Review.

PMID:
15717992
49.

Cone damage in patients receiving high-dose irofulven treatment.

Lee MS, Gupta N, Penson RT, Loewenstein J, Wepner MS, Seiden MV, Milam AH.

Arch Ophthalmol. 2005 Jan;123(1):29-34.

PMID:
15642808
50.

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.

Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.

Gynecol Oncol. 2005 Jan;96(1):198-203.

PMID:
15589601

Supplemental Content

Loading ...
Support Center